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Background/Aims: Oxidative stress results in protein oxidation and is implicated in carcinogenesis. Sulfiredoxin (Srx) is 
responsible for the enzymatic reversal of inactivated peroxiredoxin (Prx). Nuclear factor E2-related factor 2 (Nrf2) binds 
to antioxidant responsive elements and upregulates the expression of Srx and Prx during oxidative stress. We aimed to 
elucidate the biological functions and potential roles of Srx in lung cancer.
Methods: To study the roles of Srx and Prx III in lung cancer, we compared the protein levels of Nrf2, Prxs, thioredoxin, 
and Srx in 40 surgically resected human lung cancer tissues using immunoblot and immunohistochemical analyses. 
Transforming growth factor-β1, tumor necrosis factor-α, and camptothecin treatment were used to examine Prx III 
inactivation in Mv1Lu mink lung epithelial cells and A549 lung cancer cells.
Results: Prx I and Prx III proteins were markedly overexpressed in lung cancer tissues. A significant increase in the 
oxidized form of a cysteine sulfhydryl at the catalytic site of Prxs was found in carcinogenic lung tissue compared to 
normal lung tissue. Densitometric analyses of immunoblot data revealed significant Srx expression, which was higher in 
squamous cell carcinoma tissue (60%, 12/20) than in adenocarcinoma (20%, 4/20). Also, Nrf2 was present in the nuclear 
compartment of cancer cells. 
Conclusions: Srx and Prx III proteins were markedly overexpressed in human squamous cell carcinoma, suggesting 
that these proteins may play a protective role against oxidative injury and compensate for the high rate of mitochondrial 
metabolism in lung cancer. 
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INTRODUCTION
Oxidative stress and growth factor stimulation can 
cause harmful changes in DNA, proteins, and lipids. 
Signaling by reactive oxygen species (ROS), especially 
hydrogen peroxide, plays a central role in a variety 
of cellular events such as growth, proliferation, and 
carcinogenesis [1]. The lungs are constantly exposed 
to oxidative stress and xenobiotic challenges such as 
environmental pollution, toxic fumes, and cigarette smoke 
during gas exchange, and many specialized and dedicated 
proteins function as antioxidants to protect pulmonary 
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epithelial cells from the heavy oxidative stress load. These 
antioxidant-related proteins include glutathione, catalase, 
superoxide dismutase, manganese superoxide dismutase, 
nicotinamide adenine dinucleotide phosphate oxidases, 
peroxiredoxins (Prxs), and others [2]. 
Prxs are a ubiquitous family of peroxidases that function 
to protect human cells from oxidative stress. Involved 
in a number of cellular activities, Prxs remove hydrogen 
peroxide produced during normal cellular metabolism, 
growth, differentiation, inflammation, and proliferation 
[3,4]. 
Sulfiredoxins (Srxs) are a family of low molecular 
weight, sulfur-containing proteins that function to 
maintain cellular redox balance. Srx is responsible for 
enzymatically reversing inactivated Prxs, in an ATP-, 
Mg
2+-, and Ca
2+-dependent manner [5-7]. 
Nuclear factor E2-related factor 2 (Nrf2) is a well-known 
master transcription factor for antioxidant responsive 
element (ARE)-mediated protein expression [8,9]. The 
pathway involving Kelch-like ECH-associated protein 
1 (Keap1), Nrf2, and ARE-mediated protein expression 
is critical for protecting cells from both endogenous 
and exogenous stress [10,11]. A recent study using Nrf2-
knockout mice clearly demonstrated that hyperoxia-
induced expression of Srx in the lungs is dependent on the 
Nrf2-signaling pathway [12]. 
During carcinogenesis, cancer cells take advantage 
of the Nrf2/ARE protective machinery to survive the 
oxidative stress triggered by uncontrolled growth, 
chemotherapy, and radiotherapy, allowing them to endure 
the toxic effects of the therapy [13-16]. It was recently 
reported that a cigarette smoke induced-Keap1 mutation 
caused the release of Nrf2 and the activation of ARE-
mediated protein transcription, contributing to the 
development of squamous carcinoma in the head and neck 
[17,18]. However, the pathophysiological role of Nrf2 and 
its associations among the Prx and Srx proteins in human 
lung disease have not been clearly defined. 
Our aim was to elucidate the role of ROS-related signal 
transduction and to explore the associations between 
Nrf2, peroxiredoxin, sulfiredoxin, and thioredoxin (Trx) in 
human lung cancer. Thus, we examined Nrf2-dependent, 
ARE-mediated expression of Srx in human lung cancer. 
METHODS
Materials
RPMI 1640 medium, fetal bovine serum (FBS), 
trypsin-EDTA, and penicillin-streptomycin were 
purchased from Gibco BRL (Sparks, MD, USA). Alexa 
488-conjugated goat anti-mouse and anti-rabbit 
immunoglobin G (IgG), Alexa 594-conjugated goat anti-
rabbit IgG, Mitotracker Red CMXRos, and DAPI were 
purchased from Molecular Probes Inc. (Eugene, OR, 
USA). Antibodies against specific Prx isoforms and Trx 
were purchased from Young in Frontier Co. Ltd. (Seoul, 
Korea). Nrf2, anti-hemagglutinin (HA), and α-tubulin 
were obtained from Santa Cruz Biotechnology (Santa 
Cruz, CA, USA). Anti-Srx antibodies and vectors, pCGN 
and pCGN-Srx, were kindly provided by Dr. H.A. Woo 
(Ewha Womans University, Seoul, Korea). Camptothecin 
and protease inhibitor were purchased from Sigma-
Aldrich (St. Louis, MO, USA). 
Subjects
Forty patients who underwent lung cancer-related 
surgery at Ajou University Medical Center (Suwon, Korea) 
were enrolled in this study. Paired samples of tumor 
tissue and normal lung tissue were collected from each 
individual after a pathological evaluation. Informed 
consent was obtained and the study protocol was approved 
by the Internal Review Board of Ajou University Medical 
Center.
Cell culture and viability
The A549 cell line (human lung carcinoma) was 
obtained from the American Type Culture Collection 
(Manassas, VA, USA). Cells were cultured in RPMI 
1640 supplemented with 10% FBS and 1% penicillin-
streptomycin at 37°C in a humidified atmosphere 
containing 5% CO2. Cells (1 × 10
5) were seeded onto six-
well plates, cultured in RPMI containing 10% FBS for 12 
hours, and then treated with H2O2 (200 μM), transforming 
growth factor (TGF)-β1 (2 or 10 μg/mL), tumor necrosis 
factor (TNF)-α (10 μg/mL), or camptothecin (10 μM/
mL) for the indicated periods. Cells were continuously 
cultured as necessary by refreshing the medium every day 
with medium containing the same growth factors. At the 
indicated times, cells were harvested by trypsinization, 
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dead cells, and counted with a hemacytometer. The 
population of trypan blue-stained cells was counted 
using an inverted microscope (Olympus, Tokyo, Japan) to 
evaluate cellular viability. 
Transfection and depletion of siRNA
Cells were transfected with pCGN and Srx-pCGN-
HA using FuGENE HD transfection reagent (Roche 
Diagnostics, GmbH, Mannheim, Germany). Human Srx 
small interfering RNA (siRNA; SMART pool M-015263-
00-0005) and siCONTROL
® non-targeting siRNA 
were obtained from Dharmacon Research (Chicago, IL, 
USA). Cells were seeded onto six-well plates and allowed 
to reach 60% confluence. The next day, the cells were 
transfected with 20 nM Srx-siRNA or control siRNA using 
Lipofectamine RNAiMax reagent (Invitrogen, Carlsbad, 
CA, USA). 
Immunocytochemistry
Cells were grown on glass-bottom culture dishes, fixed 
with 4% paraformaldehyde, and permeabilized for 5 
minutes with 0.2% Triton X-100. The cells were incubated 
in 1 × phosphate buffered saline (PBS) containing 1% 
bovine serum albumin for 1 hour and then with primary 
antibody overnight at 4°C. After washing, the cells were 
incubated with a secondary antibody. Immunostained 
cells were washed with 1 × PBS and mounted with prolong 
GOLD (Molecular Probes). HA-tagged Srx was detected 
with anti-HA monoclonal antibody (10 μg/mL) and Alexa 
488-conjugated goat anti-mouse IgG (5 μg/mL). Prx III 
was detected with polyclonal antibodies (10 μg/mL) and 
Alexa 488-conjugated goat anti-rabbit IgG (5 μg/mL) or 
Alexa 594-conjugated goat anti-rabbit IgG (5 μg/mL). 
Mitochondria were stained with 0.1 μM MitoTracker Red 
CMXRos. Confocal fluorescence images were obtained 
using an LSM510 microscope (Carl Zeiss, MD, USA).
Co-immunoprecipitation and immunoblot analysis
For immunoblot analysis, lung tissues were homogenized 
in lysis buffer containing 50 mM Tris-HCl (pH 7.5), 150 
mM NaCl, 1 mM EDTA, 1% Triton X, and a protease 
inhibitor cocktail (Sigma-Aldrich). Cell lysates were 
centrifuged at 12,000 rpm for 10 minutes at 4°C, and the 
samples were boiled for 5 minutes in 2 × sample buffer. 
For immunoprecipitation, A549 cells were lysed in lysis 
buffer and centrifuged at 12,000 × g for 10 minutes at 
4°C. The A549 cell lysates were precleared with Protein A 
agarose beads (Upstate, Charlottesville, VA, USA), anti-
HA antibody (2 μL) was added to the lysates, and the 
lysates were rotated at 4°C for 2 hours. Protein A agarose 
beads (20 μL) were then added and the samples were 
rotated in tubes for an additional 2 hours. The samples 
were washed four times and then boiled for 5 minutes in 
1× sample buffer. The sample proteins were separated by 
sodium dodecyl sulfate polyacrylamide gels (SDS-PAGE) 
and transferred to nitrocellulose membranes (Scheicher 
and Schuell BioScience Gmbh, Dassel, Germany). After 
blocking, each membrane was incubated with primary 
antibody and then with sheep anti-mouse IgG or donkey 
anti-rabbit IgG (Amersham Biosciences, Buckinghamshire, 
UK). Immune complexes were detected by enhanced 
chemiluminescence (Amersham Biosciences).
Two-dimensional electrophoresis
A549 cells were lysed in lysis buffer (8 M urea, 4% 
CHAPS, 40 mM Tris, 20 M DTT, 0.5% IPG, pH 3-10 non-
linear) containing protease inhibitors and then sonicated 
three times with 20-s pulses. Insoluble materials were 
removed by centrifugation at 12,000 × g for 15 minutes, 
and the lysate was mixed with rehydration buffer (8 M 
urea, 2% CHAPS, 20 mM DTT, 0.5% IPG buffer, pH 
3-10 non-linear, bromophenol blue) and loaded onto 
immobilized pH gradient strips (pH 3-10 non-linear; 
Amersham Biosciences, Piscataway, NJ, USA) for 16 hours 
at room temperature. Isoelectric focusing (Amersham 
Biosciences) and preparation of the immobilized pH 
gradient strips for SDS-PAGE were conducted according to 
the manufacturer’s procedures. SDS-PAGE was performed 
in 12% gels using an Amersham Bioscience SE600 13 
cm vertical unit, and the proteins were transferred to 
nitrocellulose membranes for immunoblot analysis.
Subcellular fractionation
Cytosolic and mitochondrial-enriched fractions were 
prepared from A549 cells using a Subcellular Proteome 
Extraction kit (Calbiochem, Darmstadt, Germany). Cells 
were washed twice in ice-cold (4°C) wash buffer for 5 
minutes and then incubated with ice-cold extraction buffer 
I containing protease inhibitor cocktail for 10 minutes at 
4°C with gentle agitation. The supernatant was collected as 
the cytosolic fraction. Then, the cells were incubated with 
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cocktail for 30 minutes at 4°C with gentle agitation, and 
this supernatant was collected as the mitochondria-
enriched heavy membrane fraction.
Immunohistochemistry
Sections of paraffin wax-embedded human tissue were 
used for immunohistochemistry. After deparaffinization, 
nonspecific binding was blocked with 10% normal goat 
serum (Amersham Biosciences) and the sections were 
probed with Srx-specific polyclonal antibodies overnight 
at 4°C. Tissue sections were rinsed three times in PBS 
and incubated with streptavidin-biotin-peroxidase 
reagents (LSAB kit; Dako, Copenhagen, Denmark). 
Immunoreactivity was visualized with diaminobenzidine. 
The sections were counterstained with hematoxylin and 
eosin.
Statistical analysis
Data were analyzed at least three times using SPSS 
version 11.0 (SPSS Inc., Chicago, IL, USA). Values are 
presented as mean ± SD of triplicate determinations. 
Student’s t test was used to compare continuous data. A p 
value < 0.05 was considered statistically significant. 
RESULTS
Localization of Prx III and Srx in A549 cells
Immunocytochemical analysis followed by confocal 
microscopy demonstrated the subcellular localization 
of Prx III and Srx in A549 cells. Prx III co-localized 
specifically with the Mitotracker dye in the mitochondrial 
fraction (Fig. 1A). Srx was present in the cytosol under 
basal conditions (Fig. 1B). The localization of Srx and 
Prx III was also examined by immunoblot analysis of 
the soluble cytosolic and heavy membrane fractions. Srx 
was found predominantly in the cytosol, and Prx III was 
detected in the mitochondrial fraction (Fig. 1).
Oxidation of Prx III in mink lung epithelial cells
Mink lung epithelial cells (Mv1Lu) were exposed to 
TGF-β1 (2 ng/mL) for 72 hours, after which only the 
oxidized form of Prx III was identified by two-dimensional 
(2D) electrophoresis and immunoblot analysis (Fig. 2). 
Srx-dependent regulation of Prx III oxidation in 
A549 cells
The amount of Srx was reduced by 90% in A549 cells 
transfected with Srx-specific siRNA (20 nM) compared 
to control cells (Fig. 3A). A549 cells were treated with 
TGF-β1 (10 ng/mL) for 72 hours, and the cell lysates were 
subjected to 2D electrophoresis followed by immunoblot 
analysis. The sulfinic forms of Prx III were found only 
in A549 cells depleted of Srx, and oxidized Prx III was 
Figure 1. Expression and cellular localization of peroxir-edoxin 
(Prx) III and sulfiredoxin (Srx). A549 cells were stained for Prx 
III (FITC), Srx (FITC), and mitochondrial fraction (Mitotracker) 
and then examined by confocal microscopy (A, B). A549 cells 
were subjected to subcellular fractionation to yield mitochon-
dria-enriched heavy membrane (HM) and cytosolic fractions 
(CYF). Cell lysates were prepared and subjected to immunoblot 
analysis with antibodies to either Prx III or Srx (C).
Figure 2. Oxidation of peroxiredoxin (Prx) I, II, and III in Mv-
1Lu by transforming growth factor (TGF)-β1. Mv1Lu cells were 
cultured in DMEM containing 10% FBS and were treated with 2 
ng/mL TGF-β1 for the periods indicated. Cell lysates were ana-
lyzed with 2D gel electrophoresis, followed by immunoblot analy-
sis with indicated antibodies. Ox, oxidation, Re, reduced form. 
Prx Ⅲ
Prx Ⅲ
Srx
Srx
Mitotracker
Mitotracker
Overlay
CY F hM F
Overlay
A
b
C
pI = 3
Control
day 2
day 1
day 3
pI = 10308    The Korean Journal of Internal Medicine Vol. 26, No. 3, September 2011
http://dx.doi.org/10.3904/kjim.2011.26.3.304  http://www.kjim.or.kr
observed in A549 cells treated with either TNF-α (10 ng/
mL) or camptothecin (10 μM) for 24 hours (Fig. 4).
Nrf2-dependent, ARE-mediated expression of 
proteins in human lung cancer 
The expression levels of Nrf2, Prx, Trx, and Srx were 
examined by concomitant immunoblot analysis. The 
expression levels of Nrf2, Prxs (particularly Prx I and III), 
Trx, and Srx were higher in lung cancer tissues than in 
the paired normal lung tissues (Fig. 5). Significant Nrf2 
overexpression was observed in the nucleic fraction of lung 
cancer tissues.
Srx overexpression in human lung cancer 
We examined Srx expression in 40 resected stage I and 
II lung cancers using immunoblot analysis. Markedly 
increased Srx expression was observed in 60% of 
squamous cell carcinomas compared to the paired normal 
Figure 5. Increased expression of antioxidant responsive ele-
ment (ARE)-proteins in human lung cancer tissue (squamous 
cell carcinoma). Expression of peroxiredoxin (Prx) II, and III 
as well as thioredoxin (Trx) and sulfiredoxin (Srx) in both lung 
cancer (C) and paired normal tissue (N) was subjected to immu-
noblot analysis with antibodies to each, respectively. Expression 
of nuclear factor E2-related factor 2 (Nrf2) in both lung cancer 
(C) and paired normal tissue (N) were subjected to subcellular 
fractionation and the nucleic fraction (NR) was subjected to im-
munoblot analysis with Nrf2 antibody.
Figure 3. Sulfiredoxin (Srx) controls peroxiredoxin (Prx) III 
oxidation in A549 by transforming growth factor (TGF)-β1. Cells 
were transfected with either a control siRNA or a siRNA specific 
for human Srx mRNA, after which cell lysates were prepared 
and subjected to immunoblot analysis with antibodies to Srx 
or α-tubulin (A). Two days after cells were transfected as in (A), 
cells were exposed to 10 ng/mL TGF-β1 for 3 days and cell lysates 
were analyzed with 2D gel electrophoresis, followed by immu-
noblot analysis with Prx III antibody (B). Ox, oxidation form; Re, 
reduced form.
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Figure 4. Sulfiredoxin (Srx) controls peroxiredoxin (Prx) III 
oxidation in A549 cells by tumor necrosis factor (TNF)-α and 
camptothecin. Cells were transfected with either control siRNA 
or siRNA specific for human Srx mRNA. Two days after trans-
fection, cells were exposed to 10 ng/mL TNF-α for 24 hours (A) 
or 10 μM camptothecin for 24 hours (B) and cell lysates were 
analyzed with 2D gel electrophoresis, followed by immunoblot 
analysis with Prx III antibody. Ox, oxidation form; Re, reduced 
form.
sirNA :
Prx Ⅲ
Prx Ⅲ
Srx
Ox re re
Con
TNF- α (10 ng/mL)
Campthothecin (10μM)
A
b
Ox
Prx Ⅲ
TGF β-1 (10 ng/mL)
re re
bKim YS, et al. Overexpression of sulfiredoxin and peroxiredoxin in human lung cancer    309
http://dx.doi.org/10.3904/kjim.2011.26.3.304  http://www.kjim.or.kr
Figure 6. Increased expression of sulfiredoxin (Srx) in human lung cancer tissue: squamous cell carcinoma (A) and adenocarcinoma (B). 
Expression of Srx in both lung cancer (C) and paired normal tissue (N) were subjected to immunoblot analysis with Srx antibody.
N C N C N C N C N C N C N C N C
Srx Srx
A b
Figure 7. Expression of sulfiredoxin (Srx) in human squamous cell carcinoma. Individual data were quantified as densitometry units (A) 
and expressed as relative to the corresponding value for expression of Srx in lung cancer and paired normal tissue (B). 
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lung tissues (p < 0.001, n = 20; Fig. 6A), whereas Srx 
overexpression occurred in only 20% of adenocarcinomas 
(p < 0.001, n = 20; Fig. 6B). Srx expression levels in 
lung cancer and paired normal tissues were quantitated 
by densitometry (Fig. 7A and 8A), revealing that Srx 
was significantly overexpressed in both squamous cell 
carcinoma and adenocarcinoma cell types (Fig. 7B and 
8B). Srx protein was markedly overexpressed in all lung 
Figure 8. Expression of sulfiredoxin (Srx) in human adenocarcinoma. Individual data were quantified as densitometry units (A) and 
expressed as relative to the corresponding value for expression of Srx in lung cancer and paired normal tissue (B). 
A b
Figure 9. Expression of sulfiredoxin (Srx) and survival in all cell types of lung cancer tissue. Data are expressed as relative to the cor-
responding value for expression of Srx in all lung cancer cell types and paired normal tissue (A). Data are expressed as relative to the 
corresponding value for expression and survival of Srx in all cell types of lung cancer and paired normal tissue (B).
A bKim YS, et al. Overexpression of sulfiredoxin and peroxiredoxin in human lung cancer    311
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cancer subtypes (p < 0.001; Fig. 9A).
Srx expression and survival in lung cancer 
Srx expression level negatively correlated with patient 
survival but was not significant (Fig. 9B). 
Srx expression in lung cancer tissues 
Immunohistochemical staining of paraffin-embedded 
tissues using an anti-Srx monoclonal antibody demon-
strated that the increase in Srx protein originated from 
cancer tissue; the tumor tissue was much more heavily 
stained than the normal lung parenchyma. Srx protein 
was located mainly in the cytoplasm of cancer cells, but 
was also found in the nuclei and nucleoli (Fig. 10). 
DISCUSSION
The principal finding of this study is that Srx protein 
was markedly overexpressed in human lung squamous 
cell carcinoma. This suggests that Srx, in cooperation with 
increased levels of Prxs (particularly Prx I and III) and 
Trx, may protect pulmonary epithelial cells from oxidative 
injury. Furthermore, a significantly increased level of Nrf2 
was found in the nucleic fraction of lung cancer tissues, 
where it may regulate ARE-mediated protein expression.
It was reported previously that Prxs are expressed 
abundantly in bronchial and spulmonary epithelial cells 
[19]. However, the connection between these elevated 
protein levels and underlying overexpression mechanisms 
was not clear. Our present study showed that the 
expression levels of Nrf2, Prxs (particularly Prx I and III), 
Trx, and Srx were higher in cancer tissues than in paired 
normal lung tissues. Furthermore, Nrf2 was present at the 
site where Srx was overexpressed in lung cancer tissues. A 
previous study revealed that increased expression of Srx, 
which regenerates inactive 2-Cys Prx, relies on the Nrf2-
dependent signaling pathway [17,20-25]. Therefore, we 
Figure 10. Expression of sulfiredoxin (Srx) in human lung cancer tissue. Paraffin-fixed 5 M slide of lung cancer tissue was deparaf-
finized, incubated with Srx antibody, and visualized with DAB as the chromogen (H&E, × 400). Immunohistochemistry of adenocarci-
noma (A) and squamous cell carcinoma (B) are shown. Black arrow indicates nucleus and white arrow indicates cytoplasm. 
A
b
Adenocarcinoma
Squamous cell carcinoma312    The Korean Journal of Internal Medicine Vol. 26, No. 3, September 2011
http://dx.doi.org/10.3904/kjim.2011.26.3.304  http://www.kjim.or.kr
speculated that Nrf2 activation may be a master control 
for upregulating ARE-mediated protein expression. Our 
results are consistent with a recent report indicating 
that oxidative stress can induce Prx6 and Srx expression 
through Nrf2 in the A549 cell line [2]. However, further 
experiments with mutated Keap1 are necessary to confirm 
these findings. 
Nrf2 activation resulting from both acute and chronic 
oxidative stresses attributable to environmental car-
cinogens in smoke or to acute and chronic inflammation 
may induce subsequent ARE-mediated overexpression 
of proteins, initially protecting pulmonary epithelial cells 
from injury [26-28]. Moreover, the Keap1 mutation and 
increased ARE-mediated protein transcription have been 
identified in many patients with head and neck squamous 
cell carcinoma [17,18,29]. Thus, we believe that Srx overex-
pression in squamous carcinoma occurs in response to an 
increased level of the sulfinic form of mitochondrial Prx 
III, which is produced as a result of oxidative stress caused 
by carcinogens such as smoke and pollution or by the high 
growth and metabolic rates of tumors. The higher level 
of Srx could regenerate sulfinic Prx III to meet increased 
antioxidant demand for tumor cell survival [22]. Increased 
Nrf2 expression may be explained in the same way. Srx 
overexpression was found less frequently in adenocarcino-
ma, perhaps because adenocarcinoma tends to occur more 
often in younger, female, non-smokers, or around previous 
chronic inflammation, and is related to other genetic fac-
tors. Further studies are needed to elucidate the role of Srx 
in human lung carcinogenesis. Inhibition of Srx and inac-
tivation of Prx III may be potential therapeutic strategies 
for future lung cancer treatment.
As expected, Srx immunohistochemistry revealed 
greater staining of Srx in cancer tissues than in normal 
tissues. Previous reports have demonstrated that Srx is 
expressed in the cytoplasm [23]; however, we also found 
Srx in nuclei and nucleoli. The role of Srx protein in the 
nuclei and nucleoli should be verified by further studies. 
Oxidative stress from carcinogens increases the 
intracellular ROS level, which triggers Nrf2-dependent 
induction of Srx expression. The reduction of peroxides 
by Prx III results in its hyperoxidation to the sulfinic form 
(Prx III-SO2). The reverse reaction, which activates PRX, 
is catalyzed by Srx. Nrf2 expression and ARE-mediated 
expression of Srx, Prx I and III, and Trx are increased to 
meet the demands of tumor cell growth. 
Our study had some limitations. First, a correlation 
between patient prognosis and Srx expression was not 
verified; the observation period and number of subjects 
were insufficient to reach a statistically significant 
conclusion. Second, when we compared Nrf2 expression 
between paired normal lung and cancer tissues, it was not 
possible to separate subcellular fractions of the tissues; 
therefore, we were unable to compare Srx in the tissues. 
Third, in a few cases, Srx, Prx, and Trx expression did 
not differ between squamous cell carcinoma and paired 
normal tissues. Because squamous cell carcinoma 
develops through multifactorial processes and Srx 
induction or overexpression may participate in more than 
one pathway depending on the cellular site and individual 
tissue, Srx, Prx, and Trx expression may not be consistent 
among cases. In our experience, Srx protein has such a 
short half-life that it might have already been depleted in 
some cases.
In conclusion, the Srx and Prx III proteins were 
markedly overexpressed in a Nrf2-dependent manner in 
human squamous cell carcinoma, suggesting that these 
proteins may play a protective role against oxidative 
injury and compensate for the high rate of mitochondrial 
metabolism in lung cancer cells.
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